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Abstract
Causes of retinoid resistance often observed in neuroblastomas are unknown. We studied all trans-retinoic acid (RA) signaling in
neuroblastoma cells differing in N-myc levels in terms of neurite formation, expression of tissue transglutaminase, neuronal marker proteins,
matrix metalloproteinases (MMPs), and activation of Rac1 and Cdc42. Poor invasiveness observed in SH-SY5Y, LA-N-5, and SMS-KCNR cells
was associated with RA-induced neurite formation, Cdc42 activation and N-myc down regulation; expression of constitutively active Cdc42 down
regulated N-myc expression and reduced invasion in RA-resistant SK-N-BE(2) and IMR32 cells. RA treatment for 24 h transiently increased
invasion and expression of MMP9 in SH-SY5Y, LA-N-5 and MMP2 in SMS-KCNR cells. MMP inhibition prevented RA-induced neurite
formation indicating a role in differentiation. Variation in RA signaling thus follows a defined pattern and relates to invasive potential. A defective
RA signaling might result in retinoid resistance and unpredictable clinical outcome observed in some neuroblastomas.
Published by Elsevier B.V.Keywords: Neuroblastoma; Retinoic acid; Tissue-transglutaminase; Matrix metallo-proteinases; Rho GTPases1. Introduction
Neuroblastoma the childhood solid tumor of peripheral
nervous system accounts for 8–10% of all childhood cancers
[1]. It originates due to improper differentiation of the neural
crest cells which possess inherent tendency to migrate and
invade during the course of development [2,3] and consists of
tumorigenic ‘N’ type (neuronal) and non-tumorigenic ‘S’ type
(Schwannian) cells [4]. This cellular heterogeneity and occa-
sional spontaneous regression are the unique features of this
tumor that make prognosis difficult and clinical outcome
unpredictable [5,6]. Neuroblastoma aggressiveness and poor
prognosis is associated with N-myc amplification [7,8], that⁎ Corresponding author. Division of Molecular Cardiology, Cardiovascular
and Cancer Research Institute, Building 205, 1901 South 1st Street, Temple, TX
76504, USA. Tel.: +1 254 743 2465; fax: +1 254 743 0165.
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doi:10.1016/j.bbadis.2007.05.009also confers resistance to retinoids used in neuroblastoma
therapy [9,10]. All trans-retinoic acid (RA)-induced differentia-
tion of the ‘N’ type cells involves N-myc down-regulation
however, some of the N-myc amplified neuroblastoma cells
differentiate in response to RA, while others do not [11–14].
Signaling involved in RA induced differentiation has been
extensively studied however; a comparative analysis of RA
responses in cell lines differing in N-myc amplification has not
been attempted. Such a comparison would reveal probable
components associated with retinoid resistance. RA induces
activation of tissue-transglutaminase and Rho GTPases (Rac1
and Cdc42) during neurite formation in SH-SY5Y cells [15,16],
which represent important components of RA signaling.
Recently we also reported transient increase in invasion after
RA treatment in SH-SY5Y cells [11]. Search for possible
mechanism prompted us to study expression of matrix metal-
loproteinases (MMPs). MMPs are a family of zinc dependent
proteinases that degrade the extracellular matrix surrounding
tumor cells [17] and are divided into membrane type MMPs
(MT-MMPs), collagenases, gelatinases, stromelysins and others
[18,19]. MMP2 and MMP9 are predominantly expressed
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[20,21] and show increased expression in advanced stage
disease [22–24]. MMP expression is also regulated by N-myc
indicating a link between MMPs, N-myc and tumor spread [25].
To compare activation of RA signaling components, we
studied formation of neurite outgrowth, expression of neuronal
marker proteins (GAP43 and total tau), tissue transglutaminase
(TGase) and MMPs as well as activation of Rho GTPases (Rac1
and Cdc42) in six neuroblastoma cell lines differing in N-myc
levels. Our results show heterogeneity in RA responses that
follows a definite pattern, a differential RA signaling thus might
result in spontaneous regression and retinoid resistance
observed in some neuroblastomas.
2. Materials and methods
2.1. Cell culture and RA treatment
Neuroblastoma cell lines SH-SY5Y, IMR32, SK-N-BE(2) and SK-N-FI
(ATCC, Manassas, VA), and SMS-KCNR and LA-N-5 (a kind gift from Dr.
Reynolds, University of Southern California and Children's Hospital Los
Angeles, CA) were grown in the medium containing 10% serum and 1%
streptopenicillin at 37 °C in a humidified incubator with 5% CO2. Treatment
with RA (5 μM; Sigma, St. Louis, MO) was given in the medium containing 1%Fig. 1. RA induces neurite formation in SH-SY5Y, SMS-KCNR and LA-N-5 cells. N
the medium containing 1% serum. (A) Average neurite length in control and RA-treat
TGase, neuronal marker proteins GAP43 and total tau in control and RA-treated ce
reprobed with anti-actin antibody for normalization. Control shows expression levelsserum and the cells were incubated in the medium containing 1% serum for 12 h
prior to addition of RA. Cells treated with DMSO (vehicle) were used as a
control to compare RA responses. To study expression of MMPs, RA-treated
cells were incubated in serum free medium for additional 12 h.
2.2. Adenoviral infections
Cells were infected with adenoviruses expressing constitutively active
Cdc42 (Cdc42 V12) (a kind gift from Dr. James Bamburg, Colorado State
University, Fort Collins, CO) or GFP (control) in the medium containing 3%
serum at MOI of 50 (SK-N-BE(2) cells) or 25 (IMR32 cells) for 8 h. Activation
and expression of Cdc42 as well as invasion potential was studied after 24 h
(IMR32) or 48 h (SK-N-BE(2)).
2.3. Western blot analysis and PBD assay
Cell lysis and Western blotting was performed as described previously [26].
The cell lysates corresponding to 20 μg proteins were separated by SDS-PAGE
and Western blotted using antibodies against TGase (1:1000; Neomarkers,
Newington, NH), GAP43 (1:500) and N-myc (1:1000) (Santa Cruz
Biotechnology, Santa Cruz, CA), total tau (1:1000; Cell Signaling Technology,
Beverly, MA) or actin (1:5000; Sigma, St. Louis, MO). To study expression of
MMPs, 20 μl conditioned medium was separated by SDS-PAGE and Western
blotted with anti-MMP9 (1:500) or anti-MMP2 (1:200) (Santa Cruz
Biotechnology, Santa Cruz, CA) antibodies. Activation of Rac1 or Cdc42
was studied by affinity precipitation of GTP bound forms of these proteins
using GST (Glutathione s-transferase) fused PAK binding domain (GST-PBD)euroblastoma cells were treated with 5 μM RA or vehicle (control) for 2 days in
ed neuroblastoma cells (n=50). (B) Western blots showing expression of N-myc,
lls. Total cellular proteins (20 μg) were used for Western blotting. Blots were
in cells treated with DMSO for 2 days (maximum time point of RA treatment).
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lysates were incubated with GST-PBD beads for 1 h, washed thrice with lysis
buffer, separated on SDS-PAGE and Western blotted for Rac1 (1:1000; Cell
Signaling Technology, Beverly, MA) or Cdc42 (1:200; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Levels of Rac1 and Cdc42 in the cell lysates were
studied by Western blotting for normalization. Activation of Rac1/Cdc42 was
expressed as the ratio of GTP-Rac1/Cdc42 to total Rac1/Cdc42 after
densitometric scanning of corresponding bands.
2.4. Cell invasion assay
Cell invasion was studied using matrigel-coated transwell inserts (8 μm pore
size, 10,000 pores/cm2) as described previously [11]. Cells (2.5×105) suspended
in serum free medium were added to the upper well of transwell inserts coated
with 0.7 mg/ml matrigel matrix (BD Biosciences, Franklin Lakes, NJ). SerumFig. 2. RA differentially activates Rac1 and Cdc42 in neuroblastoma cells. Rac1 and
showing levels of GTP-Rac1 in the pull down samples and total Rac1 in the cell lysat
Rac1 was estimated by densitometric scanning and mean Rac1 activation (ratio of
Western blots showing RA-induced Cdc42 activation. Cdc42 activation was studie
showing Cdc42 activation (ratio of GTP-Cdc42 to total Cdc42) calculated from thr
treated with DMSO for 2 days (maximum time point of RA treatment).(10%) containing medium was added to the lower chamber and cells were
allowed to invade for 48 h. Invaded cells were stained, photographed using
Nikon Digital Camera under Zeiss microscope (40× magnification) and counted
(10 random fields from each transwell insert).
2.5. Gelatin zymography
Expression ofMMPswas studied in the conditioned medium by zymography
as described before [12]. Briefly, 20 μl of conditioned medium was subjected to
non-reducing SDS-PAGE gels co-polymerized with 0.1% gelatin (Sigma, St.
Louis, MO). Gels were washed with 2.5% Triton X-100 for 3 h, rinsed with
distilled water and incubated overnight in the buffer containing 50mMTris–HCl
pH 7.5, 0.2MNaCl and 5mMCaCl2 at 37 °C. Enzyme activity was visualized by
staining gels with Coomassie Brilliant Blue R250. MMP activity was quantified
by densitometric scanning of corresponding signals.Cdc42 activation was studied by GST-PBD pull down assay. (A) Western blots
es. (B) Histogram showing Rac1 activation. Intensity of signals corresponding to
GTP-Rac1 to total Rac1) was calculated from three separate experiments. (C)
d similar to Rac1 activation using GST-PBD pull down assay. (D) Histogram
ee separate experiments. Control shows activation of Rac1 and Cdc42 in cells
Table 1
Tabulated representation of RA responsiveness and invasive properties of various neuroblastoma cell lines
Cell lines Level of N-Myc
after RA treatment








SH-SY5Y + +++ +++ +++ +++
LA-N-5 + + ++ ++ +++
SMS-KCNR + + ++ ++ ++
IMR32 +++ +++
SK-N-BE ++ ++ +++
SK-N-F1 + + ++
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To study neurite outgrowth cells were treated with RA or MMP inhibitors
(Calbiochem, La Jolla, CA) in 1% serum containing medium. The medium was
replaced everyday. The cells were photographed using Nikon Digital Camera
under Zeiss microscope (40× magnification). Five random fields were
photographed and neurite outgrowth was determined by measuring length of
longest neurite per cell (n=50) using Image tool program (University of Texas
Health Science Center, San Antonio, TX).
2.7. Statistical analysis
Statistical analysis of the data was determined by one way ANOVA, paired
t-test, and Tukey–Kramer multiple comparison test. The results were considered
significant at Pb0.05.
3. Results
3.1. Neuroblastoma cells show heterogeneity in RA
responsiveness
3.1.1. Some neuroblastoma cells are resistant to RA-induced
differentiation
To study relation between N-myc amplification and RA
responsiveness in the ‘N’ type neuroblastoma cells weFig. 3. Neuroblastoma cell lines differ in invasive potential. Neuroblastoma cells wer
capacity was studied using transwell inserts coated with matrigel matrix as describ
magnification). (B) Histogram showing average number of invaded cells counted fro
times with 2 replicates each.treated N-myc non-amplified (SH-SY5Y and SK-N-FI) (Fig.
1B) [27,28] and N-myc amplified neuroblastoma cell lines
(SMS-KCNR, IMR32, SK-N-BE(2) and LA-N-5) (Fig. 1B)
[10,29,30] with RA for 2 days. RA induced neurite length
in SH-SY5Y, LA-N-5 and SMS-KCNR cells (Fig. 1A) but
not in IMR32, SK-N-BE(2) and SK-N-FI cells. RA
treatment for 24 h drastically reduced N-myc expression in
SMS-KCNR and LA-N-5 cells, while in SK-N-BE(2) cells
N-myc levels reduced after 48 h of RA treatment. In
contrast, N-myc levels remained unchanged in IMR32 cells.
TGase is shown to regulate neurite formation in SH-SY5Y
cells [16] and RA induced TGase expression in all the cell
lines except IMR32 (Fig. 1B). Two days of RA treatment
did not induce expression of neuronal marker proteins
GAP43 and total tau in SH-SY5Y, SMS-KCNR, SK-N-BE
(2) and IMR32 cells (Fig. 1B). In LA-N-5 cells, basal
expression of neuronal marker protein tau was high and
expression of GAP43 increased after RA treatment (Fig.
1B), which indicated higher differentiated state of these
cells. RA also induced GAP43 and total tau expression in
SK-N-FI cells (Fig. 1B). DMSO treatment had no effect on
the expression of N-myc, TGase, GAP43 or total tau (data
not shown).e incubated in 3% serum containing medium for 12 h after which their invasion
ed in Materials and methods. (A) Cells invaded through transwell inserts (40×
m 10 random fields from each transwell insert. Experiment was repeated three
Fig. 4. Expression of constitutively active Cdc42 reduces N-myc expression
and invasion potential. SK-N-BE(2) and IMR32 cells were infected with
adenovirus expressing constitutively active Cdc42 (Cdc42 V12) at MOI 50
and MOI 25 respectively for 8 h. (A and B) Western blots showing expression
and activation of Cdc42. Activation of Cdc42 was studied by GST-PBD pull
down assay 48 h after adenoviral infections. Cells infected with adenovirus
expressing GFP were used as a control. Cdc42 activation (ratio of GTP-Cdc42
to total Cdc42) was determined by densitometric scanning. (C) Histogram
showing number of invaded cells. Invasive potential of the cells expressing
constitutively active Cdc42 was studied 48 h after infection with adenoviruses
as described in Materials and methods. Cells expressing GFP were used as
control. The values represent mean±SD from two separate experiments with
three replicates each.
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differentiation
Rac1 and Cdc42 regulate neurite formation [15,31,32],
however RA induced Rac1 activation only in SH-SY5Y cells
(Fig. 2A, B), while basal GTP-Rac1 was higher in IMR32 cells.
Activation of Cdc42 on the other hand increased with RA
treatment in SH-SY5Y, SMS-KCNR, LA-N-5 and SK-N-FI
cells but not in SK-N-BE(2) and IMR32 cells (Fig. 2C, D).
Activation of Rac1 and Cdc42 in cells treated with DMSO for
2 days remained unchanged (data not shown). These studies
indicated that cell lines that differentiate in response to RA
show increased expression of TGase and activation of Cdc42
(Table 1).
3.1.3. Neuroblastoma cells differ in the invasive potential
Invasive potential and MMP expression was studied in
neuroblastoma cell lines. IMR32 and SK-N-BE(2) cells were
more invasive, while SH-SY5Y, SMS-KCNR and SK-N-FI
were less invasive (Fig. 3A, B). LA-N-5 cells though N-myc
amplified were least invasive which was in accordance with
highly differentiated status of these cells (Fig. 3A, B).
Differential invasion potential within N-myc amplified cells
indicated that some factors other than N-myc amplification were
involved in invasion. All the cell lines showed expression of
MMP2, however, no correlation between MMP-2 expression
and invasive potential was observed (data not shown).
3.2. Overexpression of constitutively active Cdc42 down
regulates N-myc expression and reduces invasion
To study whether RA-induced Cdc42 activation is
important for N-myc down-regulation, we infected SK-N-
BE(2) and IMR32 cells with adenovirus expressing constitu-
tively active Cdc42 (Cdc42 V12). A 5–6 fold higher
activation of Cdc42 and reduced N-myc expression was
observed in cells expressing Cdc42 V12 (Fig. 4A, B).
Constitutive activation of Cdc42 also reduced invasion
potential by 2–3 folds (Fig. 4C). Although activation of
Cdc42 is involved in cell death [33,34], over-expression of
Cdc42 did not induce cell death within the 48 h time frame
used in these studies (data not shown). Morphology of these
cells remained unaltered (data not shown) indicating that
constitutive activation of Cdc42 was not sufficient to induce
neurite formation.
3.3. RA induces invasion and MMP expression in SH-SY5Y and
SMS-KCNR cells
We have previously shown that 24 h RA treatment induces
invasion in SH-SY5Y cells [11]. RA also induced invasion in
SMS-KCNR cells but not in LA-N-5, IMR32, SK-N-BE(2) and
SK-N-FI cells (Fig. 5A) (data not shown). In SH-SY5Yand LA-
N-5 cells RA-induced MMP9 was first detected after 16 h and
8 h of RA treatment respectively, peaked at 24 h and decreased
subsequently, while in SMS-KCNR cells increased MMP2
expression was observed after 16 h of RA treatment and
remained high till 48 h (Fig. 5B–D).3.4. MMP inhibition blocks RA-induced invasion in SH-SY5Y
and SMS-KCNR cells
Invasion in SH-SY5Y and SMS-KCNR cells after RA
treatment was studied by inhibiting MMP9 and MMP2
respectively. Addition of anti-MMP9 antibody (50 μg/ml)
inhibited RA-induced invasion in SH-SY5Y cells (Fig. 6A, B).
Similarly, addition of anti-MMP2 antibody (50 μg/ml)
inhibited RA-induced invasion in SMS-KCNR cells (Fig.
7A, B). To confirm the role of MMPs in RA-induced
invasion, assay was also performed in the presence of
MMP9 inhibitor (2 μM) in SH-SY5Y cells (Fig. 6A, B)
and MMP2 inhibitor (5 μM) in SMS-KCNR cells. In the
presence of MMP9 and MMP2 inhibitors there was a
reduced invasion in SH-SY5Y and SMS-KCNR cells
respectively (Fig. 7A, B), confirming role of MMPs in
RA-induced invasion.
Fig. 5. RA induces invasion and MMP expression in SH-SY5Yand SMS-KCNR cells. SH-SY5Y, SMS-KCNR and LA-N-5 cells were treated with RA (24 h) in the
medium containing 1% serum. (A) Histogram showing number of cells invaded after RA treatment. Invasion assaywas performed as described inMaterials andmethods
and invaded cells were counted from 10 random fields from each transwell insert. The values represent mean±SD from three separate experiments with two replicates
each. Controls represent cells treated with DMSO for 2 days. (B) Zymogram (upper panel) and Western blot (lower panel) showing MMP activity and expression after
RA treatment. Gelatin zymography andWestern blottingwas performed using conditionedmedium (20 μl) as described inMaterials andmethods. (C andD)Histograms
showing mean MMP activity. Intensity of the signal in the zymogram was estimated using scanning densitometry and expressed relative to signal intensity in DMSO-
treated control samples. Values represent mean±SD from three separate experiments.
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outgrowth
Since RA-induced MMP expression was observed in SH-
SY5Y, SMS-KCNR and LA-N-5 cells which also form neurites
after RA treatment, we studied involvement of MMPs in neurite
formation. In SH-SY5Y and LA-N-5 cells when treated with
RA in the presence of MMP9 inhibitor, neurite length was
significantly reduced (Fig. 8A, B). Inhibition of MMP2
similarly inhibited RA-induced neurite formation in SMS-
KCNR cells (Fig. 8C), however cells treated with the inhibitor
rounded up and were less adherent indicating that MMP2
inhibition also affected some of the functions related to cell
survival or adhesion.
4. Discussion
Neuroblastomas are unique type of tumors, some of which
spontaneously regress, some respond to retinoid therapy andundergo regression, while others show retinoid resistance
[1,35] often due to N-myc amplification [9,36,37]. This
differential behavior might be due to cellular heterogeneity in
retinoid signaling. To identify components of heterogeneity,
we studied responses of six ‘N’ type cell lines to RA. RA
induced differentiation was associated with increased expres-
sion of TGase as well as activation of Cdc42 in RA-
responsive cells and these responses were associated with
reduced N-myc expression in the N-myc amplified SMS-
KCNR and LA-N-5 cells. Reduction in the N-myc expression
is known to be a prerequisite for RA-induced differentiation
[38,39].
N-myc amplification is associated with neuroblastoma
aggressiveness, metastasis and resistance to chemotherapy
[9,40,41] and N-myc amplified SK-N-BE(2) and IMR32 cell
lines were more invasive in nature and resistant to RA-
induced differentiation. However, this N-myc associated
invasiveness was not observed in SMS-KCNR and LA-N-5
cells, which could be due to activation of Cdc42 after RA
Fig. 6. Inhibition of MMP9 inhibits RA-induced invasion in SH-SY5Y cells. SH-
SY5Y cells were treated with RA for 24 h and invasion capacity was studied as
described in Materials and methods in the presence of 50 μg/ml anti-MMP9
antibody orMMP9 inhibitor (2μM). (A)Cells invaded through the transwell inserts
in the presence of anti-MMP9 antibody, or normal mouse IgG (50 μg/ml, used as a
control) or MMP9 inhibitor. (B) Histogram showing average number of invaded
cells. Number of invaded cells was counted from 10 random fields from each
transwell insert. The experiment was repeated three times with 2 replicates each.
1099S. Joshi et al. / Biochimica et Biophysica Acta 1772 (2007) 1093–1102treatment. Recently an opposing action between N-myc and
Cdc42 has been reported [42] and over-expression of Cdc42
V12 in SK-N-BE(2) and IMR32 cells indeed reduced
invasion along with down-regulation of N-myc expression.
SK-N-BE (2) and IMR32 cells however did not formed
neurites after expression of Cdc42 V12 indicating that
additional components are involved in neurite formation.
Sensitivity to retinoids is determined by key signaling
molecules such as cellular retinoid binding proteins, retinoid
receptors and defective retinoid signaling can result in RA
resistance [43–45]. Resistance shown by cell lines SK-N-BE
(2) and IMR32 could be due to such defects in retinoid
signaling. A balance between N-myc signaling and retinoid
signaling might play important role in neuroblastoma
progression/regression.
Similar RA responses (TGase andMMP expression as well as
Cdc42 activation) were also observed during RA induced neurite
formation in N-myc non-amplified SH-SY5Y cells. Involve-
ment of TGase and Cdc42 in neurite formation is well known
[16,31,32] and these proteins appear to be common determinants
for RA induced differentiation. Further, cell line SK-N-FI
showed only part of the RA responses; Cdc42 was activated but
TGase expression increased only slightly. These cells did not
form neurites upon RA treatment which could be due to the
absence of one of the components (TGase) necessary for neurite
formation. SK-N-FI cells are known to possess multidrug
resistance [28,46] and an altered signaling mechanism involved
in differentiation might be responsible for the observed drug
resistance.
We further studied a correlation between expression of
MMPs and invasive potential in these cell lines, however neither
found such a correlation nor found any correlation between N-
myc amplification and MMP expression which was in
accordance with studies using clinical neuroblastoma samples
[22]. On the other hand RA treatment increased MMP
expression in cell lines SH-SY5Y, SMS-KCNR and LA-N-5
and increase`d MMP expression was associated with increased
invasion in SH-SY5Y and SMS-KCNR cells. Though RA also
induced MMP9 expression in LA-N-5 cells a corresponding
increase in invasion was not observed. LA-N-5 cells are more
differentiated than the other two cell lines as indicated by
extensive neurite network formed after 24 h of RA treatment and
higher expression of neuronal marker proteins GAP43 and total
tau (Fig. 1A–C). Differentiated neuroblastoma cells are known
to lose their invasion potential [47] and hence though MMP
expression increased, LA-N-5 cells remained non-invasive. RA-
induced MMP expression has also been observed in the growth
plate chondrocytes, pluoripotent P19 cells, pancreatic cancer
cells Dan-G, chondrogenic progenitor cells ATDC5, [48–51]
and neuroblastoma cells SK-N-BE [52]. Role of MMP9 and
MMP2 in neurite process formation is well known in peripheral
neurons, Schwann cells and oligodendrocytes [53–58].
Increased MMP expression is proposed to confer invasiveness
to growing neurite [52,59] and inhibition of neurite formation in
SH-SY5Y, SMS-KCNR and LA-N-5 cells after treatment with
MMP inhibitors indicates similar involvement of MMPs in RA-
induced differentiation. During development, neural crest cells
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peripheral ganglia [3,60,61]. The transient increase in invasion
potential in SH-SY5Y and SMS-KCNR cells might mimic in
vivo differentiation process.Fig. 7. Inhibition of MMP2 inhibits RA-induced invasion in SMS-KCNR cells.
SMS-KCNR cells were treated with 5 μM RA for 24 h and allowed to invade
matrigel coated transwell inserts for 48 h in the presence of anti-MMP2 antibody
(50 μg/ml) or MMP2 inhibitor (5 μM). (A) Cells invaded in the presence of anti-
MMP2 antibody or mouse IgG (50 μg/ml, used as a control) or MMP2 inhibitor.
(B) Average number of cells that invaded matrigel matrix counted from 10
random fields from each transwell insert. The experiment was repeated three
times with two replicates each.In conclusion, our studies show heterogeneity in RA
responses within the ‘N’ type neuroblastoma cell lines. In
addition to conventional classification based on N-myc
amplification, these studies show that the cell lines could also
be classified based on RA responses. Cell lines poor in invasion
showed RA-induced neurite formation, TGase expression and
Cdc42 activation which represent markers of RA-sensitivity.
Further, RA-induced neurite formation was accompanied by
increased MMP expression and inhibition of MMPs inhibited
neurite formation. The heterogeneity observed in the present
study might explain the ineffectiveness of the drug (retinoid)
regimen followed in some neuroblastomas.
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